Nothing to add on my part. Not being secretive - simply haven't...

Nothing to add on my part. Not being secretive - simply haven't heard anything new. Story in the presentation is similar to what I've heard before though. it sounds very much like the 'most likely' partner(s) will not be making a decision until they see Phase 3 results, with the big issue being whether the higher dose of ATC can be dropped as this is apparently important for ATCs prospects of becoming part of standard combination therapies. (Of course, the biggest issue is whether ATC protects, but I think that is sort of accepted as fact now and its more a matter of how it fits into a treatment regime).